Transportation News and Press release service

Home > Transportation News
  • Aerospace News
  • Air Services News
  • Airlines News
  • Auto Dealership
  • Auto Manufacturers
  • Auto Parts News
  • Railroad News
  • Shipping News

    Watch Transportation News Video

  • E-Retailing Market Overview and Forecast 2021

    (, January 24, 2017 ) Latest Pharmaceutical and Healthcare disease pipeline guide Charcot-Marie-Tooth Disease Type I A - Pipeline Review, H2 2016, provides an overview of the Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) pipeline landscape.

    Charcot-Marie-Tooth disease type 1A (CMT1A) is a type of inherited neurological disorder that affects the peripheral nerves. Symptoms include distal weakness and atrophy, sensory loss, foot deformities, and slow nerve conduction velocity. The disorder is caused by a duplication of the PMP22 gene on Chromosome 17. Symptomatic treatment includes pain medication, physical therapy and surgery.
    For more information about this report at

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Charcot-Marie-Tooth Disease Type I A (Genetic Disorders).
    - The pipeline guide reviews pipeline therapeutics for Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Charcot-Marie-Tooth Disease Type I A (Genetic Disorders)
    Key Reasons to Purchase

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Charcot-Marie-Tooth Disease Type I A (Genetic Disorders).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Request a sample copy at
    Tables of Content:
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Global Markets Direct Report Coverage 5
    Thymic Carcinoma Overview 6
    Therapeutics Development 7
    Pipeline Products for Thymic Carcinoma - Overview 7
    Pipeline Products for Thymic Carcinoma - Comparative Analysis 8
    Thymic Carcinoma - Therapeutics under Development by Companies 9
    Thymic Carcinoma - Therapeutics under Investigation by Universities/Institutes 10
    Thymic Carcinoma - Pipeline Products Glance 11
    Clinical Stage Products 11
    Thymic Carcinoma - Products under Development by Companies 12
    Thymic Carcinoma - Products under Investigation by Universities/Institutes 13
    Thymic Carcinoma - Companies Involved in Therapeutics Development 14
    Merck & Co., Inc. 14
    Novartis AG 15
    Onxeo SA 1
    Ask for Discount at
    Contact Us:
    Call: +1-646-491-9876

    Priya Sisodia


    Source: EmailWire.Com


    Transportation Resources

    For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at
    Copyright 2007 GroupWeb Media LLC
    GroupWeb Media Network

    Aviation-NewsWire | ArtNewsWire | Auction NewsWire | CRM NewsWire | ePhotoNewsWire | Energy Industry | EstateNewsWire | | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | i-Homeland Security.Com | iMac-NewsWire.Com | i-Press-Release-Service | | iT-NewsWire.Com
    | i-TravelNewsWire.Com | MoneyNewsWire.Net | Movie-Stars-News.Com | MSNewsWire.Net | PharmaNewsWire.Com | Publishing-NewsWire.Com | RSSNewsWire.Net | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com | VoIPNewsWire.Net | XSportsWorld.Net - Newswire and Press Release service of GroupWeb Media LLC